-

11:55:34 PM

TVTX Stock News

TVTX - Travere Therapeutics Inc

06/08/23 4:30 PM

Nasdaq : TVTX

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an active

RHEA-AI

neutral

06/01/23 4:30 PM

Nasdaq : TVTX

conferences

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: William Blair 43 rd Annual Growth Stock Conference Tuesday, June 6, 2023, at 12:40 p.m. CT Jefferies Healthcare

RHEA-AI

neutral

05/31/23 7:00 AM

Nasdaq : TVTX

clinical trial

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline Pegtibatinase has been generally well-tolerated to date The Company is engaging with regulators and expects to initiate a

RHEA-AI

neutral

05/11/23 5:00 PM

Nasdaq : TVTX

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs,

RHEA-AI

very positive

05/04/23 4:01 PM

Nasdaq : TVTX

earnings

Travere Therapeutics Reports First Quarter 2023 Financial Results

FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17 th , 2023; commercial launch underway Total net product sales of $50.3 million for the first quarter of 2023, including $3.0 million for FILSPARI SAN DIEGO, May 04,

RHEA-AI

neutral

05/01/23 4:05 PM

Nasdaq : TVTX

clinical trial

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment

RHEA-AI

neutral

04/26/23 4:30 PM

Nasdaq : TVTX

conferencesearnings

Travere Therapeutics to Report First Quarter 2023 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the

RHEA-AI

neutral

04/13/23 5:00 PM

Nasdaq : TVTX

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs,

RHEA-AI

very positive

04/01/23 4:30 AM

Nasdaq : TVTX

clinical trial

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and

RHEA-AI

neutral

03/28/23 4:30 PM

Nasdaq : TVTX

conferences

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days Tuesday, April 4, 2023, at 3:55 p.m. ET

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

TVTX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww..travere.com
Security nameTravere Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees310
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Travere Therapeutics Inc

Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.